Senior Scientist Baldur Sveinbjørnsson will represent Lytix Biopharma at the conference “Melanoma: from basic science to clinical applications” that will be held in Reykjavik, Iceland on June 24-26, 2015.

Key players in the field of melanocyte and melanoma research have been invited to present their latest work on topics ranging from melanocyte development to targeted melanoma therapy. Lytix Biopharma will present a poster showing new preclinical data on the effect of LTX-315 on melanoma.

See the poster here: LTX-315 (OncoporeTM) as an oncolytic peptide immunotherapy for the treatment of melanoma